APG-2449

Phase 1Small molecule

Ascentage Pharma Group Inc.

APG-2449 is one of 3 small molecule programs targeting Advanced Solid Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid CancerRecruiting

Platinum-Resistant Recurrent Ovarian CancerRecruiting

Advanced Solid CancerPhase 1

Recruiting

Platinum-Resistant Recurrent Ovarian CancerPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Advanced Solid Cancer

#DrugCompanyPhaseTrials

SHR-A1904

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1

1 2

APG-2449

Ascentage Pharma Group Inc.

Phase 1

1 3

MHB046C

MMinghui Pharmaceutical (Hangzhou) Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Advanced Solid Cancer

NCT03917043

Q2 2028

Phase 1Recruiting

Platinum-Resistant Recurrent Ovarian Cancer

NCT06687070

Clinical

Trials by Indication[1]

Advanced Solid Cancer1 trial

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT03917043·165 enrolled

Platinum-resistant Recurrent Ovarian Cancer1 trial

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1·NCT06687070·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for APG-2449. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APG-2449 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APG-2449. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ascentage Pharma Group Inc.

APG-2449

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Trials by Indication[1]

Advanced Solid Cancer1 trial

Platinum-resistant Recurrent Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News